Literature DB >> 34848831

Expression of B7 family checkpoint proteins in cervical cancer.

Liju Zong1,2,3, Yu Gu1,3, Yuncan Zhou4, Yujia Kong1,3, Shengwei Mo2, Shuangni Yu2, Yang Xiang5,6, Jie Chen7.   

Abstract

The role of programmed cell death-ligand 1 (PD-L1) in cervical cancer has been widely investigated; however, the influences of other inhibitory B7 family members are poorly understood. We investigated the expression of PD-L1, B7 homolog 3 (B7-H3), B7-H4, and V-domain Ig suppressor of T-cell activation (VISTA) and their association with the clinicopathological features and outcomes of a large cohort of 673 patients with squamous cell carcinoma or adenocarcinoma of the uterine cervix. The positivity rates for PD-L1 (combined positive score ≥1), B7-H3 in tumor cells (TCs), B7-H4 (exclusively in TCs), VISTA in immune cells (ICs), and VISTA in TCs were 57.9%, 62.8%, 44.8%, 92.6%, and 4.8%, respectively, in 606 primary cervical cancer samples. Co-expression of PD-L1 with B7-H3 in TCs and with B7-H4 and VISTA in ICs was observed in 38.8%, 25.4%, and 57.9% of samples, respectively. B7-H3 in TCs and B7-H4 and VISTA in ICs were observed in 58.1%, 46.6%, and 83.1% of PD-L1-negative samples, respectively. These proteins were observed more frequently in squamous cell carcinomas and in moderately to poorly differentiated carcinomas. VISTA (in ICs) and B7-H4 were more frequent in primary tumors than in recurrent counterparts and correlated with improved survival; in contrast, B7-H3 positivity in TCs was less frequent in primary tumors and correlated with short disease-specific survival. Co-expression of B7-H4 and VISTA in ICs was an independent predictor of favorable outcomes overall and among patients with PD-L1-negative tumors. These data indicate that B7 family proteins exhibit differing expression patterns, distributions, and prognostic implications in cervical cancer. Furthermore, the co-expression of PD-L1 with other checkpoint proteins suggests that PD-1/PD-L1 blockade combined with modulating other immune checkpoints may present a novel therapeutic approach for cervical cancer. Future studies are needed to validate prognostic values of B7 family proteins and explore their biological roles in this malignancy.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34848831     DOI: 10.1038/s41379-021-00979-4

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  50 in total

1.  Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

Authors:  Hyun Cheol Chung; Willeke Ros; Jean-Pierre Delord; Ruth Perets; Antoine Italiano; Ronnie Shapira-Frommer; Lyudmila Manzuk; Sarina A Piha-Paul; Lei Xu; Susan Zeigenfuss; Scott K Pruitt; Alexandra Leary
Journal:  J Clin Oncol       Date:  2019-04-03       Impact factor: 44.544

2.  PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.

Authors:  Glorimar Rivera-Colon; Hao Chen; Kyle Molberg; Shuang Niu; Amanda L Strickland; Diego H Castrillon; Kelley Carrick; Katja Gwin; Jayanthi Lea; Wenxin Zheng; Elena Lucas
Journal:  Am J Surg Pathol       Date:  2021-06-01       Impact factor: 6.394

3.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Authors:  Jean-Sebastien Frenel; Christophe Le Tourneau; Bert O'Neil; Patrick A Ott; Sarina A Piha-Paul; Carlos Gomez-Roca; Emilie M J van Brummelen; Hope S Rugo; Shari Thomas; Sanatan Saraf; Reshma Rangwala; Andrea Varga
Journal:  J Clin Oncol       Date:  2017-11-02       Impact factor: 44.544

4.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

Review 5.  Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.

Authors:  Stergios Boussios; Esmeralda Seraj; George Zarkavelis; Dimitrios Petrakis; Aristomenes Kollas; Aikaterini Kafantari; Abraam Assi; Konstantina Tatsi; Nicholas Pavlidis; George Pentheroudakis
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-15       Impact factor: 6.312

Review 6.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 7.  Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.

Authors:  M B Atkins; J I Clark; D I Quinn
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

8.  Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.

Authors:  Emeka K Enwere; Elizabeth N Kornaga; Michelle Dean; Theodora A Koulis; Tien Phan; Maria Kalantarian; Martin Köbel; Prafull Ghatage; Anthony M Magliocco; Susan P Lees-Miller; Corinne M Doll
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

Review 9.  Cervical cancer.

Authors:  Steven E Waggoner
Journal:  Lancet       Date:  2003-06-28       Impact factor: 79.321

Review 10.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.